20.11
price up icon0.45%   0.09
after-market Handel nachbörslich: 20.22 0.11 +0.55%
loading

Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten

pulisher
Oct 13, 2025

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - The Motley Fool

Oct 13, 2025
pulisher
Oct 10, 2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm

Oct 10, 2025
pulisher
Oct 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm

Oct 09, 2025
pulisher
Oct 07, 2025

SciSparc And AutoMax Call Off Merger - Sahm

Oct 07, 2025
pulisher
Oct 06, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 06, 2025
pulisher
Sep 21, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva

Sep 21, 2025
pulisher
Sep 20, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva

Sep 20, 2025
pulisher
Sep 16, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm

Sep 16, 2025
pulisher
Sep 14, 2025

Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World

Sep 14, 2025
pulisher
Sep 09, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva

Sep 09, 2025
pulisher
Sep 09, 2025

Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl

Sep 09, 2025
pulisher
Aug 29, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria

Aug 29, 2025
pulisher
Aug 28, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Aug 28, 2025
pulisher
Aug 28, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa

Aug 28, 2025
pulisher
Aug 28, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se

Aug 28, 2025
pulisher
Aug 21, 2025

TEVA Stock Price and Chart — TASE:TEVA - TradingView

Aug 21, 2025
pulisher
Aug 18, 2025

Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com

Aug 18, 2025
pulisher
Aug 13, 2025

Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm

Aug 13, 2025
pulisher
Aug 12, 2025

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com

Aug 12, 2025
pulisher
Aug 06, 2025

Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva

Aug 06, 2025
pulisher
Aug 04, 2025

TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com

Aug 04, 2025
pulisher
Jul 30, 2025

Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar

Jul 30, 2025
pulisher
Jul 30, 2025

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva

Jul 30, 2025
pulisher
Jul 22, 2025

Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Jul 22, 2025
pulisher
Jul 16, 2025

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister

Jul 16, 2025
pulisher
Jun 26, 2025

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva

Jun 26, 2025
pulisher
Jun 20, 2025

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World

Jun 20, 2025
pulisher
Jun 17, 2025

Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com

Jun 17, 2025
pulisher
Jun 09, 2025

Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN

Jun 09, 2025
pulisher
May 29, 2025

Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025
pulisher
May 29, 2025

Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025
pulisher
May 28, 2025

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

May 27, 2025
pulisher
May 20, 2025

Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart

May 20, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 07, 2025

Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar

May 07, 2025
$433.61
price down icon 1.47%
$137.23
price down icon 0.09%
$54.02
price down icon 1.30%
drug_manufacturers_specialty_generic RDY
$13.97
price down icon 2.72%
$9.93
price up icon 0.71%
Kapitalisierung:     |  Volumen (24h):